SCHEMBL23623618

SCHEMBL23623618

Nc1cnc(N2CCC3(CC2)CC3)c(Cl)c1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 6/20 0.40
MAPT P10636 2/20 0.40
TP53 P04637 1/20 0.40
POLB P06746 2/20 0.39
LMNA P02545 3/20 0.36
HTT P42858 3/20 0.34
ALDH1A1 P00352 3/20 0.34
PDE9A O76083 1/20 0.34
NPSR1 Q6W5P4 2/20 0.33
KDM4E B2RXH2 1/20 0.33
AKT1 P31749 1/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
GCK P35557 1/20 0.33
PIK3CA P42336 1/20 0.33
MTOR P42345 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
GRM4 Q14833 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23623609 0.87 SMN1; SMN2 (0.39) SMN1; SMN2MAPTTP53POLBLMNA
SCHEMBL23166934 0.86 SMN1; SMN2 (0.42) SMN1; SMN2MAPTTP53POLBLMNA
SCHEMBL24215678 0.83 SMN1; SMN2 (0.41) SMN1; SMN2MAPTTP53POLBLMNA
SCHEMBL25841222 0.83 ALDH1A1 (0.44) SMN1; SMN2MAPTTP53POLBLMNA
SCHEMBL23580075 0.83 ALDH1A1 (0.49) SMN1; SMN2MAPTTP53POLBLMNA
SCHEMBL16467131 0.82 SMN1; SMN2 (0.42) SMN1; SMN2MAPTTP53POLBLMNA
SCHEMBL23623613 0.82 SMN1; SMN2 (0.40) SMN1; SMN2MAPTTP53POLBLMNA
SCHEMBL23625755 0.81 ALDH1A1 (0.51) SMN1; SMN2MAPTTP53POLBLMNA
SCHEMBL23622938 0.81 KCNJ1 (0.35) SMN1; SMN2ALDH1A1PDE9APIK3CAMTOR
SCHEMBL23623614 0.81 TRPV1 (0.38) SMN1; SMN2MAPTALDH1A1PDE9APIK3CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230127839-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY NOVARTIS PHARMA AG (CH) 2023-04-27 US disclosed
US-20230127839-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY NOVARTIS PHARMA AG (CH) 2023-04-27 US disclosed
WO-2021138419-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY IFM DUE, INC, (US) 2021-07-08 WO disclosed
WO-2021138434-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY IFM DUE, INC. (US) 2021-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230127839-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY STING1, CGAS, IRF3 SMN1; SMN2 2298/4885MAPT 3027/4885TP53 10/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.